P. Chollet

11.3k total citations · 2 hit papers
243 papers, 8.5k citations indexed

About

P. Chollet is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, P. Chollet has authored 243 papers receiving a total of 8.5k indexed citations (citations by other indexed papers that have themselves been cited), including 140 papers in Oncology, 97 papers in Cancer Research and 46 papers in Pulmonary and Respiratory Medicine. Recurrent topics in P. Chollet's work include Cancer Treatment and Pharmacology (87 papers), Breast Cancer Treatment Studies (79 papers) and HER2/EGFR in Cancer Research (28 papers). P. Chollet is often cited by papers focused on Cancer Treatment and Pharmacology (87 papers), Breast Cancer Treatment Studies (79 papers) and HER2/EGFR in Cancer Research (28 papers). P. Chollet collaborates with scholars based in France, Belgium and Italy. P. Chollet's co-authors include Xavier Durando, Catherine Abrial, H. Curé, Françis Lévi, B Perpoint, Marie‐Ange Mouret‐Reynier, Rachid Zidani, Henri Roché, Frédérique Penault‐Llorca and J Dauplat and has published in prestigious journals such as The Lancet, The Journal of Chemical Physics and Journal of Clinical Oncology.

In The Last Decade

P. Chollet

233 papers receiving 8.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil–Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer

2000 1.1k citations C. Focan, P. Chollet et al. Journal of Clinical Oncology profile →
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

2011 807 citations P. Chollet, Véronique Dièras et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
P. Chollet France	47	5.1k	2.6k	1.6k	1.5k	1.4k	243	8.5k
G. Milano France	57	7.8k 1.5×	1.5k 0.6×	4.1k 2.5×	3.1k 2.1×	1.4k 1.0×	392	12.3k
Patrick J. Flynn United States	51	6.9k 1.3×	1.6k 0.6×	2.2k 1.4×	2.6k 1.7×	2.2k 1.6×	145	11.1k
Jesús García‐Foncillas Spain	45	3.1k 0.6×	4.2k 1.6×	6.0k 3.7×	1.4k 1.0×	921 0.7×	302	10.4k
Dick J. Richel Netherlands	43	4.5k 0.9×	2.2k 0.8×	3.5k 2.2×	1.7k 1.1×	795 0.6×	107	9.6k
Mario Mandalà Italy	48	7.2k 1.4×	951 0.4×	4.8k 3.0×	1.8k 1.2×	1.2k 0.9×	271	11.8k
Ron H.J. Mathijssen Netherlands	66	7.2k 1.4×	1.7k 0.6×	5.1k 3.2×	3.5k 2.4×	859 0.6×	453	14.3k
Anna Maria Storniolo United States	47	8.7k 1.7×	3.1k 1.2×	2.7k 1.7×	2.9k 1.9×	522 0.4×	161	12.6k
James E. Krook United States	52	10.2k 2.0×	1.6k 0.6×	2.5k 1.5×	5.8k 3.9×	1.4k 1.0×	136	14.6k
Shinzaburo Noguchi Japan	64	6.1k 1.2×	5.2k 2.0×	5.1k 3.2×	2.8k 1.8×	2.1k 1.5×	389	13.7k
Hiltrud Brauch Germany	40	2.3k 0.4×	2.4k 0.9×	3.4k 2.1×	1.5k 1.0×	476 0.3×	162	6.8k

Countries citing papers authored by P. Chollet

Since Specialization

Citations

This map shows the geographic impact of P. Chollet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Chollet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Chollet more than expected).

Fields of papers citing papers by P. Chollet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Chollet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Chollet. The network helps show where P. Chollet may publish in the future.

Co-authorship network of co-authors of P. Chollet

This figure shows the co-authorship network connecting the top 25 collaborators of P. Chollet. A scholar is included among the top collaborators of P. Chollet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Chollet. P. Chollet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lévi, Françis, Carlo Garufi, Abdoulaye Karaboué, et al.. (2017). Sex-related differences in circadian-dependent tolerance of Irinotecan (I) added to chronomodulated (chrono) 5-Fluorouracil (F), Leucovorin (L) and Oxaliplatin (O): Final results from international randomised time-finding study in patients with metastatic colorectal cancer (MCC). Annals of Oncology. 28. v177–v177. 4 indexed citations

Mouret‐Reynier, Marie‐Ange, Aude-Marie Savoye, Catherine Abrial, et al.. (2015). Is It Important to Adapt Neoadjuvant Chemotherapy to the Visible Clinical Response? An Open Randomized Phase II Study Comparing Response-Guided and Standard Treatments in HER2-Negative Operable Breast Cancer. The Oncologist. 20(3). 243–244. 2 indexed citations

Chalabi, Nasséra, Catherine Abrial, Nina Radosevic‐Robin, et al.. (2015). Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?. Critical Reviews in Oncology/Hematology. 95(1). 88–104. 68 indexed citations

Praagh, Isabelle Van, et al.. (2011). Évaluation de l’observance des thérapeutiques orales en oncologie : résultats d’une étude pilote. Journal de Pharmacie Clinique. 30(2). 83–93. 3 indexed citations

Filleul, Laurent, et al.. (2010). The development of non-specific surveillance in Mayotte and Reunion Islands in the context of the epidemic of influenza A(H1N1)2009.. 283–285. 3 indexed citations

Thivat, Émilie, Olivier Lapirot, Catherine Abrial, et al.. (2010). Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse. BMC Cancer. 10(1). 648–648. 92 indexed citations

Lernout, Tinne, et al.. (2010). La grippe A (H1N1) 2009 à Mayotte: mise en place d’une surveillance épidémiologique face à la menace de pandémie. Bulletin de la Société de pathologie exotique. 104(2). 114–118. 1 indexed citations

Tubiana-Hulin, M., Véronique Becette, Ivan Bièche, et al.. (2007). Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial.. PubMed. 27(4C). 2689–96. 17 indexed citations

Penault‐Llorca, Frédérique, Catherine Abrial, Marie‐Ange Mouret‐Reynier, et al.. (2007). Achieving Higher Pathological Complete Response Rates in HER-2–Positive Patients With Induction Chemotherapy Without Trastuzumab in Operable Breast Cancer. The Oncologist. 12(4). 390–396. 7 indexed citations

10.

Roché, Henri, Pierre Kerbrat, Jacques Bonneterre, et al.. (2006). Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. Annals of Oncology. 17(8). 1221–1227. 48 indexed citations

11.

Penault‐Llorca, Frédérique, Anne Cayre, Florence Mishellany, et al.. (2003). Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. International Journal of Oncology. 22(6). 1319–25. 64 indexed citations

12.

Bent, Martin J. van den, Wolfgang Grisold, Didier Frappaz, et al.. (2003). European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Annals of Oncology. 14(12). 1732–1734. 32 indexed citations

13.

Dièras, Véronique, Philippe Bougnoux, Thierry Petit, et al.. (2002). Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin ± taxane-pretreated ovarian cancer patients. Annals of Oncology. 13(2). 258–266. 61 indexed citations

14.

Llorca, F. Penault, Xavier Sastre, Maryse Fiche, et al.. (1999). Pathological response to neoadjuvant chemotherapy Final results of a prospective randomized trial of 4AT vs 4AC as induction therapy in patients with operable breast cancer using Sataloff classification. Breast Cancer Research and Treatment. 57(1). 67. 12 indexed citations

15.

Kwiatkowski, Fabrice, et al.. (1999). Chrono-pharmacocinétique du 5-fluoro-uracile dans le traitement des cancers colorectaux métastatiques et indicateurs de réponse métabolique. Journal de Pharmacie Clinique. 18(2). 138–143. 1 indexed citations

16.

Misset, J. L., Mario Di Palma, R Plagne, et al.. (1996). Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.. Journal of Clinical Oncology. 14(4). 1136–1145. 81 indexed citations

17.

Courjal, Frank, et al.. (1992). Effect of epidermal growth factor in HLA class I and class II transcription and protein expression in human breast adenocarcinoma cell lines. British Journal of Cancer. 66(1). 88–92. 8 indexed citations

18.

Bernard, Dominique, Jean‐Claude Maurizis, J Chassagne, P. Chollet, & R Plagne. (1985). Comparison of Class II HLA antigen expression in normal and carcinomatous human breast cells.. PubMed. 45(3). 1152–8. 11 indexed citations

19.

Chollet, P., et al.. (1978). Application of cell electrophoretic methods (preparative and analytical) in demonstrating the surface heterogeneity of T-lymphocytes in man.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 28(2). 119–24. 10 indexed citations

20.

Chassagne, J, et al.. (1977). Unchanged electrophoretic mobility in human cryopreserved lymphocytes.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 27(7). 241–2. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact